Aerie Pharmaceuticals is a pharmaceutical company that specializes in the development of medications for the treatment of glaucoma and other ophthalmic diseases. Founded in 2005, Aerie has since gained significant recognition for its innovative approach to treating eye disorders and has become a leader in the field of ophthalmology. Uses: Aerie Pharmaceuticals has developed several medications for the treatment of glaucoma and other eye disorders. The company's flagship product is Rhopressa (netarsudil ophthalmic solution), which is used to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Additionally, the company has developed Rocklatan, a combination of Rhopressa and latanoprost, which was approved by the FDA in early 2019. Dosage: The recommended dosage for Rhopressa is one drop in the affected eye(s) once daily in the evening. Patients using both Rhopressa and latanoprost should administer one drop of each medication in the affected eye(s) once daily in the evening. Side Effects: Common side effects of Rhopressa include conjunctival hyperemia (redness of the eye), corneal verticillata (whorl-like patterns on the corneal surface), and eye irritation. Less common but more severe side effects may include corneal endothelial cell loss, which can lead to corneal edema (swelling), and increased risk of infection. Interactions: There are currently no known drug interactions with Rhopressa. Patients should inform their doctor of any prescription or over-the-counter medications they are currently taking, as well as any herbal supplements or vitamins. Generic: There is currently no generic equivalent of Rhopressa. The medication is protected by a patent until 2027. Demographic: Rhopressa is indicated for use in patients with open-angle glaucoma or ocular hypertension. These conditions are more common in older individuals and African Americans, and the medication is generally well-tolerated in these populations. However, the safety and effectiveness of Rhopressa and Rocklatan have not been established in children under the age of 18. Pregnant women and women who are breastfeeding should also consult their doctor before using these medications. In conclusion, Aerie Pharmaceuticals has developed two important medications for the treatment of glaucoma and other eye disorders. Rhopressa and Rocklatan have both been shown to be effective at reducing IOP, with Rhopressa offering a standalone treatment option and Rocklatan featuring a combination of Rhopressa and latanoprost. Like all medications, Rhopressa and Rocklatan come with potential side effects and interactions, and patients should consult their doctor before starting treatment. However, these medications are an important advancement in the treatment of glaucoma and offer new hope for patients seeking effective treatment options.